La Jolla Pharmaceutical Company (LJPC) Announces Completion Of Enrollment Of Phase 2 Extension Study Of GCS-100 In Chronic Kidney Disease
6/5/2014 9:14:35 AM
SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced that it has completed enrollment of GCS-100-CS-4003 (“4003 study”), its Phase 2 Extension study of GCS-100 in chronic kidney disease (“CKD”). The 4003 study was initiated to study the long-term safety and efficacy of GCS-100 in patients who completed the initial 12-week Phase 2 study (GCS-100-CS-4002). A total of 93 patients enrolled across 5 sites. Initial data from the 4003 Extension study is expected late this year.
Help employers find you! Check out all the jobs and post your resume.
comments powered by